1. Home
  2. GANX vs CUPR Comparison

GANX vs CUPR Comparison

Compare GANX & CUPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • CUPR
  • Stock Information
  • Founded
  • GANX 2017
  • CUPR 2019
  • Country
  • GANX United States
  • CUPR Singapore
  • Employees
  • GANX N/A
  • CUPR N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • CUPR
  • Sector
  • GANX Health Care
  • CUPR
  • Exchange
  • GANX Nasdaq
  • CUPR NYSE
  • Market Cap
  • GANX 53.8M
  • CUPR 43.2M
  • IPO Year
  • GANX 2021
  • CUPR 2025
  • Fundamental
  • Price
  • GANX $1.72
  • CUPR $7.30
  • Analyst Decision
  • GANX Strong Buy
  • CUPR
  • Analyst Count
  • GANX 5
  • CUPR 0
  • Target Price
  • GANX $8.20
  • CUPR N/A
  • AVG Volume (30 Days)
  • GANX 299.5K
  • CUPR 300.3K
  • Earning Date
  • GANX 08-07-2025
  • CUPR 01-01-0001
  • Dividend Yield
  • GANX N/A
  • CUPR N/A
  • EPS Growth
  • GANX N/A
  • CUPR N/A
  • EPS
  • GANX N/A
  • CUPR N/A
  • Revenue
  • GANX N/A
  • CUPR $35,406.00
  • Revenue This Year
  • GANX N/A
  • CUPR N/A
  • Revenue Next Year
  • GANX N/A
  • CUPR N/A
  • P/E Ratio
  • GANX N/A
  • CUPR N/A
  • Revenue Growth
  • GANX N/A
  • CUPR N/A
  • 52 Week Low
  • GANX $0.89
  • CUPR $3.51
  • 52 Week High
  • GANX $3.19
  • CUPR $7.46
  • Technical
  • Relative Strength Index (RSI)
  • GANX 49.29
  • CUPR N/A
  • Support Level
  • GANX $1.55
  • CUPR N/A
  • Resistance Level
  • GANX $1.79
  • CUPR N/A
  • Average True Range (ATR)
  • GANX 0.16
  • CUPR 0.00
  • MACD
  • GANX -0.00
  • CUPR 0.00
  • Stochastic Oscillator
  • GANX 44.53
  • CUPR 0.00

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About CUPR CUPRINA HOLDINGS (CAYMAN) LIMITED

Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.

Share on Social Networks: